BG Investment Services LLC Acquires 2,046 Shares of Vertex Pharmaceuticals Incorporated $VRTX

Key Points

• BG Investment Services acquired 2,046 Vertex shares worth approximately $1.07 million in the third quarter. Institutional investors and hedge funds collectively own 90.96% of the company.
• Vertex reported positive Phase 3 results for povetacicept in IgA nephropathy and plans to seek FDA accelerated approval, potentially diversifying revenue beyond its cystic fibrosis portfolio.
• Analyst sentiment remains favorable, with a consensus “Moderate Buy” rating and an average price target of $579.81, despite a slight reduction in some earnings forecasts.

BG Investment Services LLC acquired a new position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 2,046 shares of the pharmaceutical company's stock, valued at approximately $1,069,000.

A number of other institutional investors have also recently bought and sold shares of the company. Summit Global Investments acquired a new stake in shares of Vertex Pharmaceuticals in the second quarter worth about $3,568,000. Calamos Advisors LLC boosted its stake in shares of Vertex Pharmaceuticals by 77.1% during the 1st quarter. Calamos Advisors LLC now owns 77,886 shares of the pharmaceutical company's stock worth $34,779,000 after acquiring an additional 33,917 shares in the last quarter. Fideuram Intesa Sanpaolo Private Banking S.P.A. increased its holdings in shares of Vertex Pharmaceuticals by 11.9% during the 1st quarter. Fideuram Intesa Sanpaolo Private Banking S.P.A. now owns 34,991 shares of the pharmaceutical company's stock valued at $15,625,000 after acquiring an additional 3,710 shares during the last quarter. Danica Pension Livsforsikringsaktieselskab acquired a new position in shares of Vertex Pharmaceuticals during the 2nd quarter valued at about $13,823,000. Finally, UNIVEST FINANCIAL Corp acquired a new position in shares of Vertex Pharmaceuticals during the 2nd quarter valued at about $4,495,000. Institutional investors and hedge funds own 90.96% of the company's stock.

Trending Headlines about Vertex Pharmaceuticals

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Povetacicept delivered positive Phase 3 results. Vertex said the RAINIER trial met all key endpoints in IgA nephropathy, an immune-mediated kidney disease. The results were published in the New England Journal of Medicine and presented at the American Society of Nephrology meeting, supporting the drug’s potential to become an important commercial product. Vertex Pharmaceuticals Posts Positive Phase 3 Results for Povetacicept
• Positive Sentiment: Vertex plans to seek FDA accelerated approval for povetacicept in IgA nephropathy. Regulatory progress could bring a new revenue source closer and reduce the company’s reliance on its cystic fibrosis franchise. Phase 3 RAINIER Results for Povetacicept
• Positive Sentiment: Pipeline diversification is becoming more credible. About 96% of Vertex’s product sales currently come from cystic fibrosis treatments, but povetacicept and inaxaplin could expand the company into kidney disease. Inaxaplin is viewed as a potential blockbuster, adding longer-term growth optionality. Vertex Pharmaceuticals Pipeline Diversification
• Neutral Sentiment: Vertex highlighted its broader kidney-disease research program at ASN Kidney Week 2026, but the presentations do not appear to add a major new financial forecast beyond the povetacicept results. Vertex ASN Kidney Week 2026 Transcript
• Negative Sentiment: Erste Group Bank slightly reduced its EPS forecasts. The firm cut its FY2026 estimate to $16.65 from $16.68 and its FY2027 estimate to $18.97 from $19.09. While the reductions are small, they may weigh on sentiment and highlight near-term earnings uncertainty. Vertex Pharmaceuticals Analyst Estimates

Analysts Set New Price Targets

VRTX has been the topic of a number of recent analyst reports. Evercore raised their price objective on Vertex Pharmaceuticals from $535.00 to $600.00 and gave the company an "outperform" rating in a research note on Wednesday, September 2nd. UBS Group upped their target price on Vertex Pharmaceuticals from $585.00 to $615.00 and gave the stock a "buy" rating in a research report on Monday, September 28th. TD Cowen upped their target price on Vertex Pharmaceuticals from $525.00 to $550.00 and gave the stock a "buy" rating in a research report on Wednesday, September 23rd. Wall Street Zen upgraded Vertex Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Saturday, October 17th. Finally, JPMorgan Chase & Co. reiterated an "overweight" rating and set a $560.00 price target (up from $515.00) on shares of Vertex Pharmaceuticals in a report on Friday, September 11th. One analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating and three have assigned a Hold rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $579.81.

Vertex Pharmaceuticals Stock Performance

Shares of NASDAQ:VRTX opened at $523.93 on Friday. The company has a market cap of $132.97 billion, a P/E ratio of 30.50, a P/E/G ratio of 2.51 and a beta of 0.28. The stock's 50-day moving average is $523.52 and its 200-day moving average is $483.25. Vertex Pharmaceuticals Incorporated has a 52-week low of $403.16 and a 52-week high of $560.25.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its quarterly earnings data on Monday, August 3rd. The pharmaceutical company reported $4.73 EPS for the quarter, missing analysts' consensus estimates of $4.74 by ($0.01). Vertex Pharmaceuticals had a return on equity of 23.09% and a net margin of 35.00%. The business had revenue of $3.33 billion during the quarter, compared to the consensus estimate of $3.23 billion. During the same quarter in the previous year, the firm posted $4.52 earnings per share. The company's revenue for the quarter was up 12.5% on a year-over-year basis. As a group, equities analysts predict that Vertex Pharmaceuticals Incorporated will post 16.74 EPS for the current year.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on developing and commercializing medicines for serious diseases. Founded in 1989 and headquartered in Boston, Massachusetts, the company applies expertise in the science of human disease to discover therapies that address significant unmet medical needs.

Vertex is best known for its cystic fibrosis portfolio, which includes Kalydeco, Orkambi, Symdeko/Symkevi, and Trikafta/Kaftrio. These medicines target the underlying cause of cystic fibrosis for patients with specific mutations in the CFTR gene.

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.